NYSE:AMPE Ampio Pharmaceuticals (AMPE) Stock Price, News & Analysis $0.18 0.00 (0.00%) As of 06/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Ampio Pharmaceuticals Stock (NYSE:AMPE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ampio Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.18▼$0.1850-Day Range$0.01▼$0.6452-Week Range$0.00▼$0.64VolumeN/AAverage Volume2,326 shsMarket Capitalization$207.82 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ampio Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing therapies that modulate the body’s inflammatory response to alleviate pain and improve functional outcomes. Headquartered in Englewood, Colorado, the company leverages proprietary plasma‐derived and synthetic formulations to target chronic musculoskeletal and cardiovascular conditions. The company’s lead product candidate, Ampion, is a novel, low‐molecular‐weight fraction of human serum albumin designed as a single intra‐articular injection for patients suffering from osteoarthritis of the knee. Ampio is also advancing an intravenous formulation of this inflammation‐modulating technology for the treatment of acute cardiovascular injury and ischemia‐reperfusion damage. These programs are supported by preclinical studies and early‐stage clinical data demonstrating reduced inflammatory markers and improved tissue recovery. Since its inception, Ampio has built a development‐stage portfolio under the leadership of President and Chief Executive Officer Mark A. Biancamano. The company’s management team combines expertise in biologics manufacturing, clinical trial operations and regulatory affairs. Ampio maintains partnerships with contract research organizations and specialized manufacturing sites to support its pipeline advancement. Ampio Pharmaceuticals conducts its research and clinical activities primarily in the United States, collaborating with academic centers, clinical investigators and regulatory consultants. The company continues to pursue U.S. Food and Drug Administration guidance as it aims to transition its lead candidates from clinical development toward potential commercialization.AI Generated. May Contain Errors. Read More Receive AMPE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMPE Stock News HeadlinesAMPE Ampio Pharmaceuticals, Inc.June 13, 2025 | seekingalpha.comAmpio Announces Notice of Proposed Settlement of Stockholder Derivative Actions and Settlement HearingJanuary 30, 2025 | markets.businessinsider.comSpaceX will crumble without these 5 companiesThe SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.June 21 at 1:00 AM | InvestPub (Ad)Ampio Pharmaceuticals (OTC:AMPE) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comAmpio Pharmaceuticals, Inc. (AMPE)May 17, 2024 | finance.yahoo.comAmpio Pharmaceuticals Received Audit Opinion with Going Concern ExplanationApril 3, 2024 | finance.yahoo.comAmpio Pharmaceuticals Received Audit Opinion with Going Concern ExplanationApril 3, 2024 | prnewswire.comAMPE Stock Earnings: Ampio Pharmaceuticals Reported Results for Q4 2023March 27, 2024 | investorplace.comSee More Headlines AMPE Stock Analysis - Frequently Asked Questions How have AMPE shares performed this year? Ampio Pharmaceuticals' stock was trading at $0.0052 at the beginning of 2026. Since then, AMPE shares have increased by 3,421.2% and is now trading at $0.1831. How were Ampio Pharmaceuticals' earnings last quarter? Ampio Pharmaceuticals, Inc. (NYSE:AMPE) released its earnings results on Wednesday, November, 10th. The company reported ($0.40) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.40). When did Ampio Pharmaceuticals' stock split? Ampio Pharmaceuticals's stock reverse split on Tuesday, September 12th 2023.The 1-20 reverse split was announced on Thursday, August 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Ampio Pharmaceuticals? Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ampio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ampio Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Trevena (TRVN), GE Aerospace (GE) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings11/10/2021Today6/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:AMPE CIK1411906 Webampiopharma.com Phone720-437-6500Fax720-437-6501Employees20Year Founded2010Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.05Miscellaneous Outstanding Shares1,135,000Free Float1,098,000Market Cap$207.82 thousand OptionableNo Data Beta5.96 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSE:AMPE) was last updated on 6/21/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredA huge SpaceX error just led one stock to 3X move!SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
